While there are numerous local players offering generic formulations for blockbuster drugs in the erectile dysfunction drugs market, there are four companies offering branded formulations for erectile dysfunction treatment, states Transparency Market Research (TMR) in a new report. These four players in the global erectile dysfunction drugs market are Pfizer Inc., Bayer AG, Eli Lily & Co., and Dong – A Pharmaceutical Co. Ltd.
“The expiry of patents for several blockbuster drugs is paving the way for new and improved brands and generic drugs, which increases the competition in the global erectile dysfunction drugs market. This is, however, opening avenues for new entrants to capitalize on this market,” says the author of the report. There are various drugs in the pipeline that are anticipated to be more effective and safer, thereby posing a threat to existing products such as Viagra and Cialis.
The global erectile dysfunction drugs market was valued at US$4.82 bn in 2015 and is expected to reach US$3.38 bn by 2019, declining at a CAGR of 8.4% between 2015 and 2019. Geographically, North America was the leading segment in 2015 and is poised to reach US$1.81 bn by 2019. Moreover, this segment will decline at a CAGR slower than other regions during the same period. Based on brand, Cialis was the leading segment in 2015. However, by the end of 2019, Viagra is anticipated to be the leading brand with a valuation of US$1.91 bn. Zydena is expected to expand at a positive CAGR of 14.3% between 2015 and 2019. The growth of this segment can be attributed to its long duration of action and low incidence of side effects.
Hormonal Imbalance Due to Chronic Disease Drug Treatment to Encourage Uptake of Erectile Dysfunction Drugs
The growing prevalence of chronic diseases such as hypertension, diabetes, spinal cord injuries, cardiovascular diseases, and blood pressure related problems has increased the uptake of their associated drug treatments. These drugs can cause hormonal imbalance, which can lead to erectile dysfunction (ED) in men, thus contributing to the rise in demand for ED drugs.
“Growing trend of sedentary lifestyles, alcoholism and smoking can also increase the risk of ED, thereby encouraging the use of erectile dysfunction drugs,” says a TMR analyst. Other factors driving the growth of the global erectile dysfunction drugs market are the rising geriatric population and increasing campaigns by governments and NGOs worldwide to make patients aware regarding ED.
Growth of Counterfeit Medicines to Hamper Demand for Erectile Dysfunction
PDE 5 inhibitors, which are the first line treatment in ED, are associated with a major concern of the transfer of sexually transmitted diseases (STDs). Various studies indicate that the users of ED drugs have higher rates of STDs, such as HIV and Chlamydia infection than the non-users. This factor is likely to impede the growth of the global erectile dysfunction drugs market.
Moreover, growth in the trade of counterfeit medicines, especially in Asia and Europe, is posing a threat to the global erectile dysfunction drugs market. The increasing cases of adulteration and fake pharmaceuticals have reduced adoption for ED drugs from hospitals and physicians amongst patients. Another factor hampering the growth of the market is the shortage of insurance coverage for treatment of ED.
However, the novel molecule combinations and drug delivery techniques, which are safer and more effective in addressing ED are estimated to present immense growth opportunities to vendors in the global erectile dysfunction drugs market. Furthermore, the development of cheaper versions of blockbuster ED drugs in the form of generic medicines is expected to help the market expand dramatically in the forthcoming years.
The information presented in this review is based on a Transparency Market Research report, titled, ‘Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.’
The key segments of the erectile dysfunction drugs market are:
Global Erectile Dysfunction Drugs Market, by Brand
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Levitra/Staxyn (Vardenafil)
- Stendra/Spedra (Avanafil)
- Zydena (Udenafil)
- MUSE (Medicated Urethral System for Erection)
- Mvix (Mirodenafil)
- Helleva (Lodenafil Carbonate)
Global Erectile Dysfunction Drugs Market, by Pipeline
- Vitaros (Alprostadil)
- Uprima (Apomorphine)
- Others (Topiglan, Melanocortin Activators, Gene Therapy)
Global Erectile Dysfunction Drugs Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453